Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dalbavancin · 1 trial · 1 indication
To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
| Arm | Type | Description |
|---|---|---|
| Single dose Dalbavancin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Dalbavancin | DRUG | Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age. |
Inclusion Criteria: * Hospitalized patients who will be receiving at least 24 hours of appropriate non-investigational intravenous anti-infective treatment for known or suspected bacterial infections with the exception of urinary tract infections. * Written parental informed consent. * Able to comp...
Top 20 of 28 competitors
Dalbavancin is used for the treatment of bacterial infections. It is currently in Phase 1 clinical development as an investigational small molecule therapy for this indication.
Dalbavancin is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD.
Dalbavancin is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities.
Dalbavancin has one completed Phase 1 clinical trial, identified as NCT01946568. This trial investigated the pharmacokinetics and safety of a single dose of Dalbavancin in hospitalized children aged 3 months to 11 years.
Dalbavancin is also known by the name Dalbavancin, and no alternative names have been reported for this drug in clinical development.